REVB
Price
$0.86
Change
+$0.05 (+6.17%)
Updated
Jun 6 closing price
Capitalization
3.96M
TELIF
Price
$0.29
Change
+$0.01 (+3.57%)
Updated
Jun 6 closing price
Capitalization
15.9M
Interact to see
Advertisement

REVB vs TELIF

Header iconREVB vs TELIF Comparison
Open Charts REVB vs TELIFBanner chart's image
Revelation Biosciences
Price$0.86
Change+$0.05 (+6.17%)
Volume$871.55K
Capitalization3.96M
TELESCOPE INNOVATIONS
Price$0.29
Change+$0.01 (+3.57%)
Volume$75.96K
Capitalization15.9M
REVB vs TELIF Comparison Chart
Loading...
REVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REVB vs. TELIF commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REVB is a Hold and TELIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (REVB: $0.86 vs. TELIF: $0.29)
Brand notoriety: REVB and TELIF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REVB: 67% vs. TELIF: 233%
Market capitalization -- REVB: $3.96M vs. TELIF: $15.9M
REVB [@Biotechnology] is valued at $3.96M. TELIF’s [@Biotechnology] market capitalization is $15.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REVB’s FA Score shows that 2 FA rating(s) are green whileTELIF’s FA Score has 0 green FA rating(s).

  • REVB’s FA Score: 2 green, 3 red.
  • TELIF’s FA Score: 0 green, 5 red.
According to our system of comparison, both REVB and TELIF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REVB’s TA Score shows that 4 TA indicator(s) are bullish.

  • REVB’s TA Score: 4 bullish, 6 bearish.

Price Growth

REVB (@Biotechnology) experienced а +1.11% price change this week, while TELIF (@Biotechnology) price change was +34.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

REVB is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TELIF($15.9M) has a higher market cap than REVB($3.96M). TELIF YTD gains are higher at: 10.008 vs. REVB (-88.349). TELIF has higher annual earnings (EBITDA): -1.07M vs. REVB (-7.95M). REVB has more cash in the bank: 6.5M vs. TELIF (963K). REVB has less debt than TELIF: REVB (0) vs TELIF (2.15M). TELIF has higher revenues than REVB: TELIF (4.12M) vs REVB (0).
REVBTELIFREVB / TELIF
Capitalization3.96M15.9M25%
EBITDA-7.95M-1.07M741%
Gain YTD-88.34910.008-883%
P/E RatioN/A85.38-
Revenue04.12M-
Total Cash6.5M963K675%
Total Debt02.15M-
TECHNICAL ANALYSIS
Technical Analysis
REVB
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
58%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
70%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
REVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLX1.580.06
+3.95%
Protalix BioTherapeutics
PCSA0.300.01
+3.55%
Processa Pharmaceuticals
SNCY11.740.30
+2.62%
Sun Country Airlines Holdings
TALO8.020.14
+1.78%
Talos Energy
BWXT129.720.78
+0.60%
BWX Technologies

TELIF and

Correlation & Price change

A.I.dvisor tells us that TELIF and ATNM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TELIF and ATNM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TELIF
1D Price
Change %
TELIF100%
+1.31%
ATNM - TELIF
31%
Poorly correlated
+8.28%
RVXCF - TELIF
22%
Poorly correlated
N/A
ENTX - TELIF
20%
Poorly correlated
+2.99%
ACUT - TELIF
11%
Poorly correlated
+5.20%
REVB - TELIF
9%
Poorly correlated
+5.45%
More